The pharmacological activation ofPPAR-γ by the thiazolidinediones in diabetes, and of PPAR-α by the fibrates in hyperlipidemia has been shown to help to reduce inflammatory markers in preclinical and clinical studies. The gene discussed is PPARA; the disease is hyperlipidemia.